Glenmark Pharmaceuticals Limited
Financial trend (84/100) does the heavy lifting; valuation (39/100) is the drag.
Fair valueOur blended model reads Glenmark Pharmaceuticals Limited as a Buy at 61/100. We put fair value near ₹2,026.73; at ₹2,261.7 that leaves roughly 10% downside, so the stock screens fairly valued. On 45.3x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 6% below its 52-week high of ₹2,417.9 and 25% above the low of ₹1,810.4. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. The average analyst target of ₹2,496.5 implies about 10% upside across 10 analysts. It clears 9 of 13 investability checks, with durability 64, valuation 46 and momentum 67 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,621.38.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-6.46% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy61Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 14.1%
- Pass: Low debt (D/E < 0.5): 0.06x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 14%
- Pass: Earnings growing: 6575%
- Fail: Net margin ≥ 10%: 8.0%
- Pass: Current ratio > 1.5: 1.77
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 5.7
- Pass: Piotroski ≥ 7: 7/9
Quarterly results
Annual financials
Shareholding
- Promoter49.0%
- Institutions27.2%
- Public & other23.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 5.7.
- High Piotroski quality score (7/9).
Opportunities
- Earnings growing (6575% YoY).
- Revenue growing (14% YoY).
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals develops, manufactures, and sells generic, specialty, and over-the-counter pharmaceutical products across India, North America, Europe, and other markets. Its branded and generic formulations address therapeutic areas including dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system disorders, cardiology, diabetes, and gynecology.
Glenmark Pharmaceuticals Limited — frequently asked questions
Is Glenmark Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates Glenmark Pharmaceuticals Limited (GLENMARK) a Buy, based on a blended score of 61/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Glenmark Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates Glenmark Pharmaceuticals Limited's fair value at about ₹2,026.73, versus a current price of ₹2,261.7 — roughly 10% downside. On that basis the stock looks fairly valued.
Is Glenmark Pharmaceuticals Limited financially healthy?
Glenmark Pharmaceuticals Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has Glenmark Pharmaceuticals Limited's share price performed?
Glenmark Pharmaceuticals Limited is down 6% over three months, and last traded at ₹2,261.7. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.